Claims

1. Nanobody against human serum albumin, which consists of 4 framework regions (FRl to FR4 respectively) and 3 complementarity determining regions (CDRl to CDR3 respectively), in which:
CDRl comprises or is the amino acid sequence SFGMS (SEQ ID NO:36),
CDR2 comprises or is the amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO: 40), and
CDR3 comprises or is the amino acid sequence GGSLSR (SEQ ID NO: 48).

2. Nanobody against human serum albumin according to claim 1, which is chosen from the group consisting of ALB 3 (SEQ ID NO: 87), ALB 4 (SEQ ID NO: 88), ALB 5 (SEQID NO: 89), ALB 6 (SEQ ID NO: 100), ALB 7 (SEQ ID NO: 101), ALB 8 (SEQ ID NO: 102), ALB 9 (SEQ IDNO: 103) and ALB 10 (SEQ ID NO: 104).

3. The Nanobody against human serum albumin according to claim 1, in which:
(i) FR1 is an amino acid sequence chosen from the group consisting of: SEQ ID NO: 370, 368, 369, 371, 372, 373 and 374;
(ii) FR2 is an amino acid sequence chosen from the group consisting of: SEQ ID NO: 384, 383 and 385 – 388;
(iii) FR3 is an amino acid sequence chosen from the group consisting of: SEQ ID NO: 398, 396, 397, 399, 400 and 402; and
(iv) FR4 is an amino acid sequence chosen from the group consisting of: SEQ ID NO: 412, 410, 411 and 413 – 416.

4. Protein or polypeptide comprising or essentially consisting of the Nanobody according to any one of claims 1 – 3.

5. Protein or polypeptide comprising two or more Nanobodies, optionally linked via (a) linker sequence(s), said protein or polypeptide comprising at least one Nanobody according to any of claims 1 – 3.

6. Protein or polypeptide comprising three Nanobodies, optionally linked via two linker sequences, said protein or polypeptide comprising at least one Nanobody according to any of claims 1 – 3.

7. Protein or polypeptide according to claims 5 or 6, in which the linker consists of an amino acid(s).

8. Protein or polypeptide according to claim 7, in which the linker comprises at least 14 amino acids, at least 17 amino acids, or 20-40 amino acids.

9. Protein or polypeptide according to claim 7 or 8, in which the linker comprises glycine and serine residues.